Cetuximab-associated pulmonary toxicity

Clinical Colorectal Cancer

Volumn 8, Issue 2, 2009, Pages 118-120

  Chua, Wei ^a   Peters, Matthew ^a   Loneragan, Robert ^a   Clarke, Stephen ^a  

^a Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

5 Fluorouracil; Epidermal growth factor inhibitors; Oxaliplatin; Pulmonary fibrosis

Indexed keywords

AZITHROMYCIN; BEVACIZUMAB; CAPECITABINE; CEFOTAXIME; CETUXIMAB; DIURETIC AGENT; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PREDNISONE;

ABNORMAL RESPIRATORY SOUND; AGED; ARTICLE; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SIZE; CASE REPORT; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DEATH; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPNEA; HUMAN; INTERSTITIAL LUNG DISEASE; LIVER METASTASIS; LUNG FIBROSIS; LUNG INFECTION; LUNG METASTASIS; LUNG TOXICITY; LUNG VOLUME; MALE; OCCUPATIONAL EXPOSURE; RESPIRATORY FAILURE; SPIROMETRY;

EID: 68149147547     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2009.n.019     Document Type: Article

References (22)

1. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
2. Erbitux (cetuximab) Product Information: ImClone Systems Incorporated; New York, NY 10014. Available at: http://www.erbitux.com. Accessed: March 4, 2009.
3. Leard LE, Cho BK, Jones KD, et al. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant 2007; 26:1340-4.
4. Cohen MH, Williams GA, Sridhara R, et al. FDA Drug Approval Summary: Gefitinib (ZD 1839) (Iressa) tablets. Oncologist 2003; 8:303-6.
5. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial- INTACT 1. J Clin Oncol 2004; 22:777-84.
6. Herbst RS, Giaconne G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22:785-94.
7. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumour response, and survival in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2006; 24:2549-55.
8. Takano T, One Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumour response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004; 45:93-104.
9. Hotta K, Harita S, Bessho A, et al. Interstitial lung disease (ILD) during gefitinib treatment in Japanese patients with non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group. Proc Am Soc Clin Oncol 2004; 23:629 (Abstract 7063).
10. Inomata S, Takahashi H, Nagata M, et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs 2004; 15:461-7.
11. Tammaro KA, Baldwin PD, Lundberg AS. Interstitial lung disease following erlotinib in a patient who previously tolerated gefitinic. J Oncol Pharm Pract 2005; 11:127-30.
12. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004; 91(suppl 2):S18-S23.
13. Endo M, Johkoh T, Kimura K, et al. Imaging of gefitinib-related interstitial lung disease: Multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 2006; 52:135-40.
14. Higenbottom T, Kuwano K, Nemery B et al. Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer 2004; 91(suppl 2):S31-S37.
15. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevaling and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-51.
16. Suzuki H, Aoshiba K, Yokohari N, et al. Epidermal growth factor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 2003; 63:5054-9.
17. Ishii Y, Fujimoto S, Fukuda T. Gefitinib prevents bleomycin-induced lung fibrosis in mice. Am J Respir Crit Care Med 2006; 174:550-6.
18. Rice AB, Moomaw CR, Morgan DL, et al. Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol 1999; 155:213-21.
19. Saijo A, Maemondo M, Gomi K, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361:137-9.
20. Nagaria NC, Cogswell J, Choe JK, et al. Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol 2005; 23:2423-4.
21. Kitajima H, Takahasho H, Harada K, et al. Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers. Respirology 2006; 11:217-20.
22. Kataoka K, Taniguchi H, Hasegawa Y, et al. Interstitial lung disease associatedwith gefitinib. Respir Med 2006; 100:698-704.